RT Journal Article
T1 Adverse outcomes in patients with heart failure admitted for COVID‑19 in association with the use of renin-angiotensin‑aldosterone system inhibitors.
A1 Perez-Belmonte, Luis M
A1 Sanz-Canovas, Jaime
A1 Salinas, Alejandro
A1 Garcia-Klepzig, Jose Luis
A1 Mendez-Bailon, Manuel
A1 Gomez-Huelgas, Ricardo
AB Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a global health crisis [1]. Patients with cardiovascular disease seem particularly susceptible to severe COVID-19 [2]. Among patients hospitalized for COVID-19, heart failure (HF) has been reported as a factor associated with potential risk for worse outcomes [3,4]. However, to date, specific data on the clinical profile, course, and prognosis of patients with a history of HF are limited [4-6].
YR 2021
FD 2021-10-22
LK http://hdl.handle.net/10668/21747
UL http://hdl.handle.net/10668/21747
LA en
NO Pérez-Belmonte, L. M., Sanz-Cánovas, J., Salinas, A., Garcia-Klepzig, J. L., Méndez-Bailón, M., & Gómez-Huelgas, R. (2022). Adverse outcomes in patients with heart failure admitted for COVID‑19 in association with the use of renin-angiotensin‑aldosterone system inhibitors. Polish archives of internal medicine, 132(1), 16126.
DS RISalud
RD Apr 6, 2025